دورية أكاديمية
Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis.
| العنوان: | Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis. |
|---|---|
| المؤلفون: | Schepers EJ; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Glaser K; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Zwolshen HM; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Hartman SJ; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Bondoc AJ; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. |
| المصدر: | Cancer research [Cancer Res] 2023 Jun 15; Vol. 83 (12), pp. 1933-1940. |
| نوع المنشور: | Review; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Baltimore, Md. : American Association for Cancer Research Original Publication: Chicago [etc.] |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/pathology , Glypicans*/chemistry , Glypicans*/genetics , Glypicans*/metabolism , Liver Neoplasms*/pathology, Humans ; Carcinogenesis ; Protein Processing, Post-Translational |
| مستخلص: | Glypican-3 (GPC3) is a cell-surface glycoprotein that is frequently overexpressed in hepatocellular carcinoma (HCC). GPC3 undergoes extensive posttranslational modification (PTM) including cleavage and glycosylation. This review focuses on the structure and function of GPC3 in liver cancer, highlighting the PTM of the tertiary and quaternary structures of GPC3 as a potential oncogenic regulatory mechanism. We propose that the function of GPC3 in normal development can vary with extensive PTM and that dysregulation of these processes leads to disease. Defining the regulatory impact of these modifications can provide a deeper understanding of the role of GPC3 in oncogenesis, epithelial-mesenchymal transition, and drug development. Through review of current literature, this article provides a unique perspective on the role of GPC3 in liver cancer, focusing on potential regulatory mechanisms of PTM on GPC3 function at the molecular, cellular, and disease level. (©2023 The Authors; Published by the American Association for Cancer Research.) |
| References: | Mech Dev. 2005 Jul;122(7-8):928-38. (PMID: 15925496) Clin Transl Med. 2017 Dec;6(1):18. (PMID: 28510121) Oncotarget. 2017 Jun 20;8(25):41211-41226. (PMID: 28476031) J Biol Chem. 2015 Mar 20;290(12):7576-85. (PMID: 25653284) J Hepatocell Carcinoma. 2016 Nov 08;3:63-67. (PMID: 27878117) Am J Clin Pathol. 2008 Jun;129(6):899-906. (PMID: 18480006) Nat Genet. 2000 Mar;24(3):245-50. (PMID: 10700176) J Cell Sci. 2022 Mar 15;135(6):. (PMID: 35142364) Dev Biol. 2001 Mar 1;231(1):31-46. (PMID: 11180950) Front Oncol. 2019 Aug 02;9:708. (PMID: 31428581) Nat Rev Mol Cell Biol. 2013 Jul;14(7):416-29. (PMID: 23719536) Toxins (Basel). 2016 Sep 22;8(10):. (PMID: 27669301) Biosci Rep. 2019 Sep 24;39(9):. (PMID: 31511432) Am J Pathol. 2018 Sep;188(9):1973-1981. (PMID: 29935166) J Cancer. 2020 Feb 3;11(8):2008-2021. (PMID: 32127929) Oncol Lett. 2018 Jul;16(1):970-976. (PMID: 29963171) Dev Cell. 2001 Aug;1(2):251-64. (PMID: 11702784) Annu Rev Biochem. 1999;68:729-77. (PMID: 10872465) J Cell Biochem. 2005 Dec 1;96(5):897-905. (PMID: 16149080) Gastroenterology. 2003 Jul;125(1):89-97. (PMID: 12851874) Breast Cancer Res Treat. 2003 Jul;80(2):221-32. (PMID: 12908826) Dev Cell. 2008 May;14(5):700-11. (PMID: 18477453) Matrix Biol. 2019 Jan;75-76:220-259. (PMID: 29128506) J Urol. 2005 Nov;174(5):1826-7. (PMID: 16217300) J Surg Res. 2023 Feb;282:118-128. (PMID: 36272230) Biochim Biophys Acta. 2002 Dec 19;1573(3):241-6. (PMID: 12417406) Proc Natl Acad Sci U S A. 2010 May 4;107(18):8248-53. (PMID: 20404163) J Cell Biol. 1995 Sep;130(5):1207-18. (PMID: 7657705) Breast Cancer Res Treat. 2009 Mar;114(2):251-62. (PMID: 18404367) Hepatology. 2019 Oct;70(4):1231-1245. (PMID: 30963603) Cancer Res. 2005 Jul 15;65(14):6245-54. (PMID: 16024626) Cancer Res. 2008 Dec 1;68(23):9832-8. (PMID: 19047163) Matrix Biol. 2014 Apr;35:248-52. (PMID: 24412155) Hepatology. 2007 May;45(5):1298-305. (PMID: 17464972) Hepatology. 2019 Aug;70(2):563-576. (PMID: 30353932) Am J Pathol. 2013 Jul;183(1):153-9. (PMID: 23665349) J Cell Biol. 2003 Nov 10;163(3):625-35. (PMID: 14610063) J Cell Biol. 1998 Jun 15;141(6):1407-14. (PMID: 9628896) Oncotarget. 2016 Sep 13;7(37):60133-60154. (PMID: 27507057) Front Oncol. 2020 Feb 21;10:195. (PMID: 32154182) Cancer Rep. 2011;1(1):14-19. (PMID: 22563565) Oncoimmunology. 2017 Sep 27;7(1):e1377872. (PMID: 29296538) Front Oncol. 2022 Feb 16;12:824208. (PMID: 35251989) J Cancer Res Clin Oncol. 2018 Dec;144(12):2399-2418. (PMID: 30267212) Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083-91. (PMID: 23471984) J Pediatr Hematol Oncol. 2001 Nov;23(8):496-9. (PMID: 11878776) J Cell Sci. 2012 Jul 15;125(Pt 14):3380-9. (PMID: 22467855) J Cell Biochem. 2013 Mar;114(3):625-31. (PMID: 23060277) Commun Biol. 2021 Sep 8;4(1):1049. (PMID: 34497364) Hepatology. 2010 May;51(5):1712-23. (PMID: 20432255) Nature. 2000 Apr 13;404(6779):725-8. (PMID: 10783877) EMBO Rep. 2009 Aug;10(8):901-7. (PMID: 19590577) Liver Res. 2020 Dec;4(4):168-172. (PMID: 33384879) Cancer Sci. 2009 Aug;100(8):1403-7. (PMID: 19496787) Dev Biol. 1997 Oct 1;190(1):78-93. (PMID: 9331333) Dev Cell. 2004 Oct;7(4):503-12. (PMID: 15469839) J Biol Chem. 2005 Dec 16;280(50):41201-6. (PMID: 16227623) FEBS Lett. 2014 Jan 21;588(2):377-82. (PMID: 24140348) FASEB J. 2003 Jul;17(10):1215-27. (PMID: 12832286) Oncol Lett. 2017 Dec;14(6):6327-6333. (PMID: 29391876) Gynecol Oncol. 2010 Nov;119(2):332-6. (PMID: 20701957) Int J Oncol. 2015 Mar;46(3):1275-85. (PMID: 25572615) J Cell Biol. 1999 Jul 12;146(1):255-64. (PMID: 10402475) Nat Commun. 2015 Mar 11;6:6536. (PMID: 25758784) Nat Genet. 1996 Mar;12(3):241-7. (PMID: 8589713) J Hepatol. 2016 Aug;65(2):289-95. (PMID: 27085251) Cell Mol Life Sci. 2011 Mar;68(6):923-9. (PMID: 18087675) Am J Med Genet. 1998 Oct 2;79(4):279-83. (PMID: 9781908) Hum Mutat. 2018 Jun;39(6):790-805. (PMID: 29637653) Biochem Pharmacol. 2019 Oct;168:108-118. (PMID: 31251939) Curr Opin Cell Biol. 2000 Oct;12(5):575-80. (PMID: 10978892) Anticancer Agents Med Chem. 2011 Jul;11(6):549-59. (PMID: 21554202) Nat Commun. 2020 Nov 20;11(1):5915. (PMID: 33219207) Mol Carcinog. 2005 Nov;44(3):151-61. (PMID: 16167351) PLoS One. 2015 Sep 02;10(9):e0137664. (PMID: 26332121) Sci Rep. 2016 May 17;6:26245. (PMID: 27185050) Int J Cancer. 2000 Sep 20;89(5):418-22. (PMID: 11008203) Eur J Cancer. 2011 Feb;47(3):333-8. (PMID: 21112773) Science. 2003 Mar 28;299(5615):2039-45. (PMID: 12663920) Breast Cancer Res Treat. 2010 Feb;119(3):559-74. (PMID: 19288189) Orphanet J Rare Dis. 2014 Sep 20;9:138. (PMID: 25238977) Glycobiology. 2001 Mar;11(3):19R-23R. (PMID: 11320054) Am J Med Genet. 2001 Aug 1;102(2):161-8. (PMID: 11477610) Biochem Biophys Res Commun. 2003 Jun 20;306(1):16-25. (PMID: 12788060) World J Pediatr Surg. 2021 Jun 8;4(3):e000220. (PMID: 36474976) Int J Cancer. 2010 Mar 15;126(6):1291-301. (PMID: 19816934) Cancer Res. 1997 Nov 15;57(22):5179-84. (PMID: 9371521) Gut. 2001 Apr;48(4):558-64. (PMID: 11247902) Cancer Res. 2004 Apr 1;64(7):2418-23. (PMID: 15059894) Carcinogenesis. 2008 Jul;29(7):1319-26. (PMID: 18413366) Neoplasia. 2011 Aug;13(8):735-47. (PMID: 21847365) Int J Cancer. 2003 Feb 10;103(4):455-65. (PMID: 12478660) J Biol Chem. 2005 Jan 21;280(3):2116-25. (PMID: 15537637) J Hepatol. 2013 Nov;59(5):1107-17. (PMID: 23835194) Nat Cell Biol. 2008 Jul;10(7):761-3. (PMID: 18591969) |
| معلومات مُعتمدة: | P30 DK078392 United States DK NIDDK NIH HHS |
| المشرفين على المادة: | 0 (Glypicans) 0 (GPC3 protein, human) |
| تواريخ الأحداث: | Date Created: 20230407 Date Completed: 20230619 Latest Revision: 20230622 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10267680 |
| DOI: | 10.1158/0008-5472.CAN-22-3895 |
| PMID: | 37027004 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-7445 |
|---|---|
| DOI: | 10.1158/0008-5472.CAN-22-3895 |